18-086 - A Randomized, Open-Label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Status: open

18-086 - A Randomized, Open-Label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Treatment for Pancreatic Cancer

Contact Us Or call (251) 445-9834

Description

This is an open-label, phase 2 comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients with advanced pancreatic adenocarcinoma who have not received prior chemotherapy. IRB 18-086

Providers Associated With This Trial

Principle Investigator

This link will open in a new tab or window.